CAR-T Cell Therapy in China: Costs, Hospitals, and What International Patients Should Know

CAR-T cell therapy is one of the most significant breakthroughs in cancer treatment in the past decade. For patients with certain blood cancers who have exhausted conventional options, it can offer complete remission where nothing else has worked. But in the United States, a single infusion of CAR-T cells costs $400,000 to $500,000 — and that is just the drug itself, before hospitalization and follow-up care.

In China, the same category of treatment costs $80,000 to $150,000, including hospitalization. That is up to 80% less than in the US, with clinical outcomes that are comparable to Western therapies.

This guide covers everything international patients need to know about receiving CAR-T therapy in China: how it works, which products are approved, what it costs, where to get treated, and how to navigate the process from abroad.

What Is CAR-T Cell Therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a form of immunotherapy — but unlike checkpoint inhibitors or other drugs, CAR-T uses your own living immune cells as the treatment.

Here is how it works:

1. Collection. Doctors draw blood and extract T-cells (a type of white blood cell central to immune function) through a process called leukapheresis.
2. Engineering. In a specialized laboratory, those T-cells are genetically modified to express a chimeric antigen receptor (CAR) on their surface. This receptor is designed to recognize a specific protein found on the surface of cancer cells.
3. Expansion. The engineered CAR-T cells are multiplied in the lab over two to four weeks until there are hundreds of millions of them.
4. Infusion. The CAR-T cells are infused back into the patient's bloodstream, where they seek out and destroy cancer cells carrying the target antigen.

Why CAR-T Is Called a "Living Drug"

Unlike conventional chemotherapy, which is a chemical compound that decays in the body, CAR-T cells are alive. Once infused, they can:

• Actively hunt cancer cells by recognizing specific surface antigens (most commonly CD19 for B-cell cancers or BCMA for multiple myeloma)
• Kill repeatedly — a single CAR-T cell can destroy multiple cancer cells in succession
• Multiply inside the body, amplifying the immune response over days and weeks
• Form memory cells that persist for months or years, providing ongoing surveillance against relapse

This is why a single infusion can sometimes produce durable remissions lasting years — something that repeated rounds of chemotherapy often cannot achieve.

Which Cancers Does CAR-T Treat?

As of early 2026, CAR-T therapy is approved for and clinically proven against the following hematologic (blood) cancers:

• Diffuse Large B-Cell Lymphoma (DLBCL) — the most common indication; for patients who have relapsed after or are refractory to two or more lines of systemic therapy
• Follicular Lymphoma (FL) — relapsed or refractory after two or more lines of therapy
• Mantle Cell Lymphoma (MCL) — relapsed or refractory disease
• B-Cell Acute Lymphoblastic Leukemia (ALL) — primarily in pediatric and young adult patients with relapsed or refractory disease
• Multiple Myeloma (MM) — after multiple prior lines of therapy, using BCMA-targeted CAR-T products

What about solid tumors? CAR-T therapy for solid tumors (lung, liver, pancreatic, gastric cancers) remains in the clinical trial phase worldwide. The challenges are significant — solid tumors create hostile microenvironments that suppress immune cells, and their surface antigens are more heterogeneous. However, dozens of clinical trials are underway in China and globally, and breakthroughs are anticipated in the coming years. If you are interested in clinical trial access, contact our team for the latest information.

China's Approved CAR-T Products

China's National Medical Products Administration (NMPA) has approved several CAR-T products for commercial use. Unlike the US, where only a handful of products from Novartis (Kymriah) and Bristol Myers Squibb/2seventy bio (Abecma, Breyanzi) dominate the market, China has developed a competitive domestic CAR-T industry that has driven prices significantly lower.

NMPA-Approved CAR-T Products (as of Early 2026)

Several additional products are in late-stage clinical trials, including BCMA-targeted therapies for multiple myeloma and next-generation CD19 products with improved persistence. As more products reach the market, competition is expected to drive prices even lower.

How Chinese CAR-T Products Compare to US-Approved Therapies

Chinese CAR-T products target the same antigens (CD19, BCMA) and use similar manufacturing processes as their Western counterparts. Published clinical trial data shows:

• Overall Response Rate (ORR): 70-83% — comparable to Yescarta (83%) and Kymriah (52-82%) in the US
• Complete Remission Rate (CR): 40-54% — consistent with global benchmarks
• Safety profiles are similar, with Cytokine Release Syndrome (CRS) and neurotoxicity as the primary side effects, managed with established protocols

The key difference is not efficacy — it is cost.

Cost Breakdown: China vs. the US vs. Europe vs. Japan

Global Price Comparison

For an American patient, the savings from traveling to China for CAR-T therapy can be $300,000 to $500,000 — even after accounting for travel, accommodation, and a medical tourism facilitator.

What Does the Total Cost Include in China?

A complete CAR-T treatment cycle in China typically costs $95,000 to $190,000 in total. Here is a breakdown:

These figures are based on published hospital pricing and OriEast client data. Actual costs vary depending on the specific CAR-T product used, hospital, disease complexity, and whether complications arise.

Why Is CAR-T So Much Cheaper in China?

Several factors contribute to China's lower pricing:

• Domestic manufacturing. Chinese biotech companies (Fosun Kite, JW Therapeutics, and others) manufacture CAR-T products locally, avoiding the import markups and licensing fees that inflate Western prices.
• Government policy. China's government has invested heavily in cell and gene therapy as a strategic industry, providing subsidies, tax incentives, and streamlined regulatory pathways to domestic manufacturers.
• Hospital competition. Multiple major medical centers now offer CAR-T, creating competitive pressure that keeps prices in check.
• Lower operational costs. Laboratory labor, hospital stays, and clinical infrastructure cost less in China than in the US or Europe.
• No middleman markups. In the US, drug pricing involves layers of intermediaries (PBMs, hospital chargemasters, payer negotiations) that inflate the final bill. Chinese hospital pricing is more direct.

Insurance and Payment

CAR-T products are not yet covered by China's national health insurance for international patients. However:

• International health insurance: Some global insurance plans (Cigna Global, Bupa International, Allianz Care) may cover CAR-T therapy abroad. Check your policy for "cross-border treatment" or "medical tourism" provisions. OriEast can provide the documentation your insurer requires.
• Payment methods: Chinese hospitals accept wire transfers and, in some cases, credit card payments. OriEast can facilitate the payment process and provide itemized invoices for insurance reimbursement claims.
• Payment timing: Most hospitals require a deposit before treatment begins, with the balance due before discharge. The CAR-T product itself is typically the first major payment milestone.

Top Hospitals for CAR-T Therapy in China

CAR-T therapy requires specialized infrastructure: an experienced hematology/oncology team, access to certified GMP cell manufacturing facilities, an ICU capable of managing severe CRS, and robust post-infusion monitoring protocols. Not every hospital can offer it.

The following are among the leading centers in China for CAR-T treatment, all of which are OriEast partner hospitals or referral institutions.

Shanghai

Shanghai is China's leading hub for CAR-T therapy, with the highest concentration of experienced treatment centers and clinical trial activity.

Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)

Ruijin is widely considered the top hematology hospital in China. Its National Research Center for Translational Medicine has been at the forefront of CAR-T clinical research since the early trial phases. The hospital has treated hundreds of CAR-T patients and publishes extensively in international journals. Its hematology department is led by physicians who have trained and collaborated with leading US and European institutions.

• Strong track record in DLBCL, ALL, and multiple myeloma
• Extensive experience with both commercial products and clinical trial therapies
• International patient services available

Zhongshan Hospital (Fudan University)

One of China's top-ranked comprehensive hospitals, Zhongshan offers CAR-T as part of its broader oncology and hematology programs. The hospital is known for its multidisciplinary approach, which is especially valuable for patients with complex medical histories or co-morbidities that require coordinated care across specialties.

• Multidisciplinary tumor board review for all CAR-T candidates
• Strong ICU and critical care support
• Experience with international patients across multiple departments

Renji Hospital (Shanghai Jiao Tong University School of Medicine)

Renji has deep expertise in lymphoma and multiple myeloma, making it a particularly strong choice for patients with these diagnoses. The hospital has participated in multiple pivotal CAR-T clinical trials and has published notable outcomes data.

• Specialized lymphoma and myeloma programs
• Active clinical trial portfolio for next-generation CAR-T products
• Collaborative relationship with Fosun Kite and other domestic manufacturers

Beijing

Peking University People's Hospital

Home to one of China's designated National Key Disciplines in Hematology, Peking University People's Hospital is a leading center for blood cancer treatment in northern China. It has extensive experience with both autologous and allogeneic stem cell transplants, which provides a strong foundation for managing CAR-T patients — especially those who may need transplant as a consolidation strategy.

• National Key Discipline in Hematology
• Large patient volume and extensive CAR-T experience
• Strong research output in cell therapy

Peking Union Medical College Hospital (PUMCH)

PUMCH consistently ranks among the top hospitals in China across all specialties. Its strength lies in its multidisciplinary coordination and the depth of its specialist teams. For CAR-T patients who present with unusual complications or complex diagnostic questions, PUMCH's breadth of expertise is a significant advantage.

• Top-ranked comprehensive hospital in China
• Exceptional multidisciplinary consultation capability
• International medical department with English-speaking staff

Other Major Centers

• First Affiliated Hospital of Zhejiang University (Hangzhou) — a pioneer in CAR-T clinical research in China, with some of the earliest and largest published datasets
• Tongji Hospital, Huazhong University of Science and Technology (Wuhan) — the leading hematology center in central China, with growing CAR-T experience
• First Affiliated Hospital of Sun Yat-sen University (Guangzhou) — the primary CAR-T treatment center for southern China

For detailed hospital profiles and to discuss which center is the best fit for your diagnosis, visit our hospital directory or request a case evaluation.

The Treatment Timeline: What to Expect

The entire CAR-T treatment process typically takes 6 to 8 weeks from initial evaluation to hospital discharge. Here is a week-by-week overview of what international patients can expect.

Week 1: Eligibility Assessment and Workup

Upon arrival at the hospital, your medical team will conduct a comprehensive evaluation to confirm that you are an appropriate candidate for CAR-T therapy. This includes:

• Review of prior treatment records — pathology reports, imaging, treatment history
• Fresh diagnostic workup — PET-CT scan, bone marrow biopsy, flow cytometry
• Organ function assessment — cardiac echocardiography, pulmonary function tests, liver and kidney panels
• Infection screening — HIV, hepatitis B/C, CMV, and other relevant tests
• Performance status evaluation — to ensure you can tolerate the treatment

Not all patients who arrive for evaluation will be approved for CAR-T. If your disease has progressed beyond certain thresholds, or if organ function is insufficient, the medical team may recommend alternative approaches. This honest assessment is important — it protects patients from undergoing a treatment that is unlikely to benefit them.

Week 1-2: Leukapheresis (T-Cell Collection)

Once eligibility is confirmed, the next step is leukapheresis — a procedure to collect your T-cells from peripheral blood. The process is similar to blood donation:

• You are connected to an apheresis machine via an IV line in each arm
• Blood is drawn from one arm, T-cells are separated out, and the remaining blood components are returned through the other arm
• The procedure takes approximately 3 to 4 hours
• No anesthesia is required, and most patients experience minimal discomfort

The collected T-cells are then shipped to a certified GMP manufacturing facility for engineering.

Weeks 2-5: CAR-T Cell Manufacturing

This is the "waiting" phase. Your T-cells are being genetically modified and expanded in the laboratory. The manufacturing process typically takes 2 to 4 weeks.

During this period:

• You may be able to return home or stay at nearby accommodations (discuss with your medical team)
• If your disease is progressing and needs to be controlled, the team may administer bridging therapy — a short course of chemotherapy or targeted therapy to keep the cancer in check while CAR-T cells are being manufactured
• OriEast can arrange accommodation and daily support during this waiting period

Week 5-6: Lymphodepletion Chemotherapy

Three to five days before the CAR-T infusion, you will receive lymphodepletion (or "conditioning") chemotherapy. The standard regimen is:

• Fludarabine (30 mg/m2 daily for 3 days) + Cyclophosphamide (500 mg/m2 daily for 3 days)

The purpose is to deplete your existing lymphocytes, creating "space" in the immune system for the CAR-T cells to expand effectively after infusion. This is a critical step — studies have shown that adequate lymphodepletion significantly improves CAR-T efficacy.

Side effects of lymphodepletion are generally mild and transient: fatigue, nausea, and temporary drops in blood counts.

Week 6: CAR-T Cell Infusion (Day 0)

The infusion itself is surprisingly brief and uneventful for most patients:

• The CAR-T cells are thawed (if cryopreserved) and administered via standard IV infusion
• The infusion takes approximately 15 to 30 minutes
• You will be monitored closely for immediate reactions, though serious infusion reactions are rare
• Pre-medications (acetaminophen, diphenhydramine) are typically given to reduce the risk of mild infusion reactions

Day 0 — the day of infusion — marks the beginning of the most intensive monitoring period.

Weeks 6-8: Monitoring and Side Effect Management

After infusion, you will remain hospitalized for a minimum of 2 weeks (and sometimes up to 4 weeks) for close monitoring. This is the phase where the CAR-T cells are expanding in your body and engaging with cancer cells, which can trigger significant immune reactions.

The two primary side effects that require monitoring are Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), discussed in detail below.

Most patients are ready for discharge 2 to 4 weeks after infusion, once side effects have resolved and vital signs are stable.

Post-Discharge: Follow-Up and Response Assessment

After discharge, follow-up evaluations are typically scheduled at:

• 1 month post-infusion — first response assessment (PET-CT, lab work)
• 3 months — interim evaluation
• 6 months — key milestone for determining durable response
• 12 months and beyond — long-term surveillance

For international patients, the initial 1-month follow-up should ideally be done at the treating hospital in China. Subsequent follow-ups can often be coordinated with your oncologist at home, with OriEast facilitating the transfer of records and communication between medical teams.

Managing Side Effects: CRS and ICANS

CAR-T therapy is powerful, but it carries real risks. The two most important side effects are directly related to the mechanism of action — when CAR-T cells attack cancer cells, they trigger intense immune responses that can affect the entire body.

Cytokine Release Syndrome (CRS)

CRS occurs when activated CAR-T cells release large quantities of cytokines (inflammatory signaling molecules) into the bloodstream. It is the most common side effect of CAR-T therapy, occurring in 50-90% of patients to some degree.

Grading and symptoms:

Key facts about CRS:

• Onset is typically 1 to 14 days after infusion, with peak symptoms around days 3-7
• Grade 1-2 CRS is the most common presentation and is manageable with standard interventions
• Grade 3-4 CRS occurs in approximately 10-20% of patients and requires ICU-level care
• Tocilizumab, an IL-6 receptor antagonist, is the primary treatment for CRS and is highly effective. All CAR-T treatment centers in China stock tocilizumab and have protocols for rapid escalation.
• CRS is almost always reversible with appropriate management. Fatal CRS is rare in modern CAR-T practice.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS is a neurological side effect that can occur alongside or after CRS. It reflects the impact of immune activation on the central nervous system.

Symptoms may include:

• Confusion, disorientation, difficulty finding words
• Tremor, impaired handwriting
• Headache, drowsiness
• In severe cases: seizures, cerebral edema (very rare)

Key facts about ICANS:

• Occurs in approximately 20-60% of CAR-T patients, depending on the product and disease
• Usually appears 3 to 10 days after infusion
• Most cases are Grade 1-2 (mild confusion, word-finding difficulty) and resolve within days
• Severe ICANS (Grade 3-4) occurs in about 10-15% of patients and is treated with corticosteroids
• Like CRS, ICANS is almost always reversible

How Chinese Hospitals Manage These Risks

The CAR-T treatment centers listed above have dedicated protocols for CRS and ICANS management that align with international guidelines (ASTCT consensus grading, NCCN recommendations). Specifically:

• 24/7 monitoring during the high-risk window (days 0-14 post-infusion)
• Tocilizumab on-site and ready for rapid administration
• ICU availability for patients who develop Grade 3-4 CRS
• Neurology consultation available for ICANS assessment
• Standardized grading tools (Lee criteria for CRS, ICE score for ICANS) used to guide treatment decisions

Chinese hospitals have now treated thousands of CAR-T patients and have developed deep institutional experience in managing these complications. This experience is a critical factor in patient safety.

Clinical Efficacy: What the Data Shows

Published clinical trial data and real-world evidence from Chinese CAR-T programs demonstrate outcomes that are competitive with global benchmarks.

Response Rates

These figures represent patients with relapsed or refractory large B-cell lymphoma — the most common indication. Results vary by disease type, patient fitness, prior treatment history, and which CAR-T product is used.

Important Context

• "Complete remission" does not always mean "cure." Some patients in CR will eventually relapse. However, patients who remain in CR at 12 months have a significantly higher probability of long-term disease-free survival.
• CAR-T works best as part of a comprehensive treatment strategy. Some patients may benefit from consolidation therapy (such as allogeneic stem cell transplant) after achieving remission with CAR-T.
• Earlier treatment may yield better results. Emerging data suggests that CAR-T used in earlier lines of therapy (second-line rather than third-line or beyond) may produce higher response rates and more durable remissions. Discuss timing with your oncologist.

How International Patients Access CAR-T Treatment in China

Traveling abroad for cancer treatment is a significant decision. OriEast exists to make the process as straightforward and safe as possible. Here is how it works.

Step 1: Submit Your Medical Records for Review

Start by submitting your medical records through our free case evaluation. Include:

• Pathology reports (diagnosis, immunohistochemistry, molecular markers)
• Most recent PET-CT or CT scan reports and images
• Summary of all prior treatments (chemotherapy regimens, radiation, transplant history)
• Current lab work (CBC, CMP, LDH, beta-2 microglobulin if applicable)

Our medical team will review your case within 3 to 5 business days and provide a preliminary assessment of CAR-T eligibility.

Step 2: Remote Consultation with a Chinese Specialist

If your case is potentially suitable for CAR-T, we will arrange a video consultation between you and a hematologist/oncologist at one of our partner hospitals. This consultation will cover:

• Confirmation of CAR-T candidacy based on your full medical history
• Recommended CAR-T product and treatment center
• Estimated timeline and cost
• Any questions you or your family have

Step 3: Travel and Logistics Planning

Once you decide to proceed, OriEast handles the logistics:

• Medical visa assistance — we provide the hospital invitation letter required for a Chinese medical visa (M visa)
• Hospital admission scheduling — coordinated with the treatment center to minimize wait times
• Accommodation — we arrange nearby housing for the patient and accompanying family members, suitable for extended stays of 6-8 weeks
• Airport transfers and local transportation
• 24/7 bilingual medical coordinator — an OriEast team member who speaks your language accompanies you to all appointments, translates during consultations, and serves as your point of contact throughout the treatment

Step 4: Treatment in China

During your treatment, OriEast provides:

• Full-time medical interpretation at all hospital visits, consultations, and procedures
• Daily check-ins during hospitalization
• Coordination with your home oncologist — we can arrange for regular updates and share records with your doctor back home
• Assistance with insurance documentation — itemized invoices and medical summaries formatted for reimbursement claims

Step 5: Discharge and Ongoing Care

Before you leave China, we ensure:

• A comprehensive discharge summary is prepared in English
• Follow-up imaging and lab work recommendations are clearly documented
• Your home oncologist receives a full treatment report
• A schedule for remote follow-up consultations with the Chinese medical team is established, if desired

Learn more about our CAR-T therapy services and broader cancer treatment programs.

Frequently Asked Questions

Is CAR-T treatment in China as safe and effective as in the US?

Yes. Chinese CAR-T products target the same antigens, use similar manufacturing processes, and have demonstrated comparable efficacy and safety in published clinical trials. The hospitals that administer CAR-T in China follow international management guidelines for CRS and ICANS. The primary difference is cost — not quality.

How long do I need to stay in China?

Plan for 6 to 8 weeks from arrival to discharge. This includes the initial evaluation, T-cell collection, the manufacturing waiting period, conditioning chemotherapy, infusion, and post-infusion monitoring. We recommend allowing up to 2 months to accommodate any unexpected treatment adjustments. The first follow-up assessment at 1 month post-infusion is ideally done in China as well, which could extend the total stay to approximately 10 weeks.

Is the CAR-T infusion painful?

The infusion itself is a standard IV procedure lasting 15 to 30 minutes. It is not painful. However, in the days following infusion, most patients will experience some degree of CRS symptoms — fever, fatigue, body aches — which can range from mild to severe. The medical team manages these symptoms proactively.

What is the success rate?

For relapsed/refractory large B-cell lymphoma (the most common CAR-T indication), published data shows an overall response rate of 70-83% and a complete remission rate of 40-54%. Outcomes depend on the specific diagnosis, disease burden, prior treatments, patient fitness, and the CAR-T product used. Your consulting physician can provide a more individualized prognosis.

What happens if CAR-T does not work or I relapse?

Options after CAR-T failure or relapse include:

• Second CAR-T infusion using a different product or targeting a different antigen
• Allogeneic stem cell transplant (if not previously performed and the patient achieves a sufficient response)
• Bispecific antibodies — a newer class of immunotherapy now available in China
• Clinical trials — China has a robust pipeline of next-generation cell therapies in clinical trials
• Targeted therapies — depending on the specific cancer type and molecular profile

Your medical team will discuss all available options based on your individual situation.

Can I receive CAR-T in China for solid tumors?

Not through commercially approved products. As of 2026, all NMPA-approved CAR-T therapies are indicated for hematologic (blood) cancers only. However, there are active clinical trials in China exploring CAR-T for liver cancer, gastric cancer, pancreatic cancer, and other solid tumors. If you are interested in clinical trial participation, contact us and we can investigate current eligibility criteria.

Do I need a companion or caregiver during treatment?

We strongly recommend having at least one family member or trusted companion with you for the duration of treatment. While OriEast provides a dedicated medical coordinator, having someone familiar with you is important for emotional support, especially during the post-infusion monitoring period when CRS symptoms may occur. OriEast arranges accommodation suitable for both patients and accompanying family members.

How do I pay for treatment?

Payment is typically made via international bank wire transfer directly to the hospital. Some hospitals also accept credit cards for certain portions of the bill. OriEast provides a clear cost estimate before you travel and helps coordinate the payment timeline. We also provide detailed invoices and medical documentation formatted for insurance reimbursement claims back home.

Can OriEast help coordinate with my oncologist at home?

Absolutely. We routinely work with patients' home oncologists to ensure continuity of care. This includes sharing treatment records, arranging phone or video consultations between your Chinese and home medical teams, and preparing comprehensive English-language discharge summaries. Ongoing follow-up after you return home can be coordinated remotely.

Related Resources

• CAR-T Therapy Services at OriEast — detailed overview of our CAR-T treatment facilitation program
• Cancer Treatment in China — other oncology services available through OriEast
• Proton Therapy in China: Costs, Centers, and Treatment Guide — another advanced cancer treatment option in China
• Our Partner Hospitals — profiles of the medical centers we work with
• Free Case Evaluation — submit your records for a preliminary assessment

Disclaimer: This article is for informational purposes only and does not constitute medical advice. CAR-T cell therapy eligibility, costs, and outcomes vary based on individual patient circumstances, disease type, and treatment center. Pricing information is based on publicly available data and OriEast client experience as of March 2026; actual costs may differ and should be confirmed directly with the treating hospital. All treatment decisions should be made in consultation with qualified medical professionals. OriEast is a medical travel facilitation service and does not provide medical treatment directly. If you would like to determine whether CAR-T therapy may be appropriate for your situation, please submit your records through our free case evaluation for review by our medical advisory team.